INDIVIDUAL PEPTIDE PROFILE
PTD-DBM
PTD-DBM is a synthetic research peptide developed at Yonsei University in South Korea, combining a cell-penetrating protein transduction domain (PTD) with a Dishevelled-binding motif (DBM) copied from the protein CXXC5. It is studied in mouse and cell models for its ability to reactivate the Wnt/beta-catenin signaling pathway involved in hair follicle formation, and it has no history of human study.
WHAT IT IS
PTD-DBM was designed by researchers in Kang-Yell Choi's laboratory at Yonsei University as a tool to block the interaction between CXXC5, a zinc-finger protein that suppresses Wnt/beta-catenin signaling, and Dishevelled (Dvl), a protein central to that same pathway. Blocking this interaction is intended to restore Wnt signaling that promotes hair follicle formation.
It is a peptide construct made of a cell-penetrating transduction domain fused to a short binding motif, rather than a naturally occurring hormone or a cosmetic ingredient, and all published work on it involves topical application in mouse models or incubation with cultured cells.
It is a research peptide with no approved human use, no established human dosing, and no clinical trials registered on ClinicalTrials.gov as of current public research. It should not be confused with FDA-approved hair loss treatments such as minoxidil or finasteride.
WHAT RESEARCHERS ARE STUDYING IT FOR
Published research on PTD-DBM has looked at:
- Wound-induced hair follicle neogenesis in mice, alone and in combination with the drug valproic acid
- Restoration of hair growth suppressed by prostaglandin D2 (PGD2), a molecule associated with androgenetic alopecia, in mouse models
- Upregulation of beta-catenin signaling in cultured human dermal papilla cells
- The role of CXXC5 as a negative regulator of Wnt signaling in skin and hair follicle biology more broadly
PROPOSED BIOLOGICAL MECHANISMS
The proposed mechanism is that PTD-DBM physically competes with CXXC5 for binding to Dishevelled, freeing Dishevelled to activate the Wnt/beta-catenin pathway, which in turn supports the signaling cascade needed to initiate new hair follicle growth.
Because CXXC5 has also been linked to PGD2-driven and DHT-driven pathways implicated in androgenetic alopecia in later mouse work from the same research group, PTD-DBM has been studied as a way to counteract multiple upstream drivers of hair loss in animal models.
All mechanistic evidence to date comes from mouse skin and cultured human cells; how this pathway behaves in living human skin and scalp tissue has not been established.
AREAS OF RESEARCH INTEREST
- Whether findings in mouse wound-healing and hair-follicle models translate to human scalp biology, which differs from mouse skin in structure and follicle cycling
- Human pharmacokinetics, including how much of a roughly 3,000-dalton peptide can cross human skin topically, given that molecules this size penetrate intact skin poorly
- Any registered human safety or efficacy trials, none of which have been published or registered to date
- How PTD-DBM's effects compare with small-molecule compounds later developed by the same laboratory targeting the same CXXC5 pathway
WHAT THE EVIDENCE CURRENTLY SUGGESTS
A 2017 study from the Choi laboratory reported that topical PTD-DBM, particularly combined with valproic acid, promoted wound-induced hair follicle neogenesis in mice and increased beta-catenin activity in human dermal papilla cells grown in culture.
A 2023 follow-up study from the same group reported that PTD-DBM treatment could restore hair growth suppressed by PGD2 in mice, adding further mechanistic support for the CXXC5 target, again entirely in animal and cell models.
FDA status: PTD-DBM is a research peptide with no FDA-approved use in humans; it is not evaluated, reviewed, or approved by the FDA for any indication, and it has not been studied in registered human clinical trials.
Promising mouse data, no human evidence yet
A LABORATORY TARGET WITH REAL MECHANISTIC INTEREST, STILL ENTIRELY PRECLINICAL
PTD-DBM comes from a legitimate, published line of academic research into the Wnt/beta-catenin pathway and hair follicle biology, which sets it apart from many unverifiable research-peptide claims circulating online.
That legitimacy applies specifically to the mouse and cell-culture findings. No human trial data, human safety data, or human efficacy data for PTD-DBM currently exist in the published literature.
The same research group has since pursued small-molecule compounds targeting the same CXXC5 pathway, which is worth noting when weighing how central PTD-DBM itself remains to this line of research.
Research Reality Check
What we know
PTD-DBM is a Wnt/beta-catenin-activating research peptide that has shown hair follicle regeneration effects in mouse wound and PGD2-suppression models, along with increased beta-catenin signaling in cultured human dermal papilla cells, published by a single academic research group.
What remains uncertain
Whether these mouse and cell-culture findings would replicate in living human scalp tissue, whether a roughly 3,000-dalton peptide can meaningfully penetrate human skin topically, and whether any human safety or efficacy data will ever be generated for this specific compound.
Educational commentary, not personal testimonial
The Balanced Body Lifestyle Take
PTD-DBM is a good illustration of how far preclinical science can be from something people should actually use. As an ISSA Certified Personal Trainer and Nutritionist, I find the Wnt/beta-catenin hair biology genuinely interesting, and I also think it is important to say plainly that mouse data is not human data.
If PTD-DBM or hair-focused research peptides more broadly have caught your attention, reach out to us. We can talk through what drew you to it and look at what the current research does and does not show.
QUESTIONS PEOPLE OFTEN ASK
SOURCES & FURTHER READING
- Journal of Investigative Dermatology: Choi lab, activation of hair follicle regeneration via CXXC5/Dishevelled interaction disruption (PTD-DBM)
- PMC / Cells: CXXC5 mediates DHT-induced androgenetic alopecia via PGD2, PTD-DBM treatment in mice
- U.S. Food and Drug Administration: research chemicals and unapproved drugs are not lawful for human use
Peptide Education Consultation
Interested in learning more about peptides? Schedule an educational consultation with Vince Angelo to discuss the information and ask questions.
Schedule an Educational ConsultationEDUCATIONAL NOTICE
The Balanced Body Lifestyle™ provides peptide and wellness information for educational purposes only. Content is intended to help readers better understand emerging research, established evidence and areas of scientific uncertainty. It is not medical advice, diagnosis, treatment guidance or a recommendation to use any medication, peptide or research compound. Decisions involving prescription medications or investigational compounds should be discussed with a qualified healthcare professional.
THE BALANCED BODY LIFESTYLE
A healthy life is built on balance.